Eiko Lifesciences Ltd
Incorporated in 2021, Eiko LifeSciences
Ltd manufacturing & sells Specialty
Chemical and Fine Chemicals[1]
- Market Cap ₹ 66.5 Cr.
- Current Price ₹ 53.5
- High / Low ₹ 81.3 / 46.8
- Stock P/E
- Book Value ₹ 4.67
- Dividend Yield 0.00 %
- ROCE -103 %
- ROE -48.5 %
- Face Value ₹ 10.0
Pros
- Debtor days have improved from 113 to 39.8 days.
Cons
- Stock is trading at 11.4 times its book value
- Company has low interest coverage ratio.
- Promoter holding is low: 24.2%
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | TTM | |
|---|---|---|---|---|
| 2.36 | 4.27 | 10.81 | 5.22 | |
| 1.98 | 4.95 | 15.29 | 7.39 | |
| Operating Profit | 0.38 | -0.68 | -4.48 | -2.17 |
| OPM % | 16.10% | -15.93% | -41.44% | -41.57% |
| 0.04 | 0.04 | 0.09 | 0.03 | |
| Interest | 0.09 | 0.19 | 0.35 | 0.22 |
| Depreciation | 0.08 | 0.17 | 0.19 | 0.18 |
| Profit before tax | 0.25 | -1.00 | -4.93 | -2.54 |
| Tax % | 20.00% | 21.00% | 26.77% | |
| 0.20 | -0.78 | -3.62 | -1.85 | |
| EPS in Rs | 0.31 | -0.69 | -2.98 | -1.55 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -40% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 18% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 4% |
| 3 Years: | -4% |
| 1 Year: | -21% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | -49% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Sep 2020 | |
|---|---|---|---|---|
| Equity Capital | 3.82 | 3.82 | 3.82 | 3.82 |
| Reserves | 1.74 | 1.10 | -0.87 | -0.83 |
| 1.74 | 1.37 | 1.61 | 1.81 | |
| 3.66 | 3.01 | 7.49 | 7.19 | |
| Total Liabilities | 10.96 | 9.30 | 12.05 | 11.99 |
| 1.68 | 1.71 | 1.75 | 1.68 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 3.17 | 1.72 | 0.10 | 0.15 |
| 6.11 | 5.87 | 10.20 | 10.16 | |
| Total Assets | 10.96 | 9.30 | 12.05 | 11.99 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | |
|---|---|---|---|
| 0.00 | 0.16 | -0.33 | |
| 0.00 | -0.30 | -0.71 | |
| 0.00 | -0.55 | 0.95 | |
| Net Cash Flow | 0.00 | -0.69 | -0.09 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | |
|---|---|---|---|
| Debtor Days | 225.81 | 73.51 | 39.84 |
| Inventory Days | 819.93 | 287.76 | 136.40 |
| Days Payable | 605.69 | 174.40 | 163.59 |
| Cash Conversion Cycle | 440.04 | 186.87 | 12.65 |
| Working Capital Days | 267.56 | 78.64 | -145.86 |
| ROCE % | -11.83% | -102.92% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Updates on Acquisition 19 Apr
-
Certificate Under Regulation 40(9) Of SEBI (LODR ) Regulations, 2015
17 Apr - Certificate for the year ended 31st March 2024 issued by Shravan A. Gupta & Associates , Practicing Company Secretary in compliance with Regulation 40(9)of SEBI …
- Compliance Certificate Under Regulation 7(3) Of Securities Exchange Board Of India (Listing Obligation And Disclosure Requirements) Regulation 2015 For The Financial Year Ended 31St March, 2024 17 Apr
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 12 Apr
- Closure of Trading Window 27 Mar
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Business Overview:[1]
ELL is in the business of manufacturing, processing, formulating, producing, buying, selling, and exporting specialty and Fine Chemicals comprising organic & inorganic chemicals, and Pharma Intermediates, etc.